Nearly 350 people joined a virtual public meeting that the Foundation for Sarcoidosis Research (FSR) ran as part of a U.S. Food and Drug Administration (FDA) program to discuss the unmet needs and challenges faced by those living with sarcoidosis. In the Externally Led Patient-Focused Drug Development meeting,…
Nonsteroidal immunosuppressants may be a treatment option for people with cardiac sarcoidosis who don’t respond well to corticosteroids or have side effects from using them, a Japanese study suggests. While nonsteroidal immunosuppressants reduced the need for corticosteroids and how active sarcoidosis lesions were for some patients, more research is…
A 30-year-old man with renal cell carcinoma — a type of kidney cancer — developed sarcoid-like reactions in his spleen, liver, and lungs, which went away after the tumor’s removal, suggesting that such reactions arose from an unusual immune response against the tumor. The man’s case was described in a…
The Foundation for Sarcoidosis Research (FSR) has awarded $100,000 in funding to support U.S.-based research projects aimed at improving knowledge and diagnosis of cardiac sarcoidosis, a type of sarcoidosis that affects the heart. The funds were split into two cardiac sarcoidosis-specific grants, of $50,000 each. One…
The prognosis for people with cardiac sarcoidosis may depend on the condition of their heart at diagnosis and not on whether other organs are also affected, a study in Japan suggests. Isolated cardiac sarcoidosis, where the disease is limited to the heart, is a significant risk factor for worse…
For a young man in Belgium, a month-long headache combined with slurred speech and walking difficulties were the result of neurosarcoidosis, or sarcoidosis affecting the nervous system, a case study shows. The man’s neurosarcoidosis was part of a widespread form of sarcoidosis affecting multiple other organs, including the…
This year’s Global Virtual Sarcoidosis Summit, hosted by the Foundation for Sarcoidosis Research (FSR), is bringing together the sarcoidosis community under the theme “Find Your Community, Find Your Life.” Those interested in taking part in the summit, happening virtually from Nov. 3 to 5, can register…
Meitheal Pharmaceuticals has entered into an agreement with Xentria to market XTMAB-16, the investigational treatment for pulmonary sarcoidosis, should it be approved in the future. Under the terms of the agreement, Meitheal gains the sole rights to sell and distribute XTMAB-16 in North America. Xentria retains the…
Bellerophon Therapeutics is working toward launching a new Phase 2 trial to test INOpulse, its experimental device for inhaled nitric oxide, in people who develop pulmonary hypertension as a complication of sarcoidosis (PH-Sarc). The announcement was part of a company’s clinical program update that stated…
The Foundation for Sarcoidosis Research (FSR) has trained its first group of volunteer patients tasked with educating and championing better treatments and outcomes for people living with sarcoidosis in the U.S. The 60 newly trained volunteer leaders will team up with and support members of the foundation’s…
Get regular updates to your inbox.